Sumitomo Dainippon Pharma Annual Report 2017
48/102

Sumitomo Dainippon Pharma has enacted a basic policy stipulating the Company’s fundamental approach to risk management and has developed a system to appropriately promote risk management for the Group. Under this promotional framework, according to the particularities of each risk, risks are divided into those requiring a horizontal, group-wide approach, and those requiring specific approaches by each company. The Company keeps track of the risk management of the group companies as a whole through reports from each group company, and provides each group company with its guidance, advice and the like when necessary.In order to address risks bearing an impact on business activities, we have enacted the internal “Risk Management Rule” that clarifies the President’s role in overseeing risk management, and specifies a system for promoting risk management of each specific risk. One of the Company’s specific initiatives is to carry out annual risk assessments and formulate necessary countermeasures based on the results followed by implementation and evaluation. This is undertaken systematically by each section of the Company working on the solution to each problem.Additionally, Sumitomo Dainippon Pharma has formulated a business continuity plan (BCP) from the viewpoint of stable supply of the pharmaceutical products that is our social mission, and with the plan assuming the occurrence of a large-scale disaster and an infectious pandemic of new strains of influenza. Furthermore, in order to bolster ability to cope with disasters, etc., the Company has prepared necessary rules and manuals corresponding to each anticipated risk. Employees are educated on these matters through specific training and seminars that the Company holds.Executive Officer in charge of ComplianceBoard of DirectorsComplianceSumitomo Dainippon Pharma has declared in our publicly announced Declaration of Conduct our commitment to “comply with laws and regulations, and conduct transparent and fair corporate activities with a good sense of ethics.” To put this declaration into practice and ensure full compliance, we have established Compliance Standards and use them as concrete guidelines for business activities.One of Sumitomo Dainippon Pharma’s executive officers is charged with overseeing all compliance matters of Sumitomo Dainippon Pharma and its group companies around the world. Three compliance committees have been set up: the Compliance Committee of Sumitomo Dainippon Pharma, the Compliance Committee of the group companies in Japan and the Compliance Committee of the group companies outside Japan. The Sumitomo Dainippon Pharma executive officer in charge of compliance serves as chair of each of the three committees and reports to the Board of Directors on the committee activities. In fiscal 2016, each compliance committee held two meetings and the details of those meetings were reported to the Board of Directors.Sumitomo Dainippon Pharma has set up internal and external compliance hotlines through which its officers and employees can make consultations and reports relating to incidents of real or threatened compliance violation, and the Company operates such compliance hotline in an appropriate manner. Similar compliance hotlines have been installed in the group companies in and outside Japan. The officers and employees of such group companies may use the Sumitomo Dainippon Pharma hotlines, if the use of their own compliance hotlines is not appropriate.Risk ManagementSumitomo Dainippon Pharma has formulated a Business Continuity Plan (BCP) assuming that the occurrence of predicted earthquakes, including an earthquake occurring directly beneath the Tokyo metropolitan area and a large-scale earthquake in the Nankai Trough. Regular training is being carried out to practice disaster response measures. In July 2016, drills were held assuming a large-scale earthquake in the Sanin (western coastal) area of Japan, while drills addressing a Tokyo metropolitan earthquake were held in March 2017. Furthermore, for the purpose of quickly gathering information on employees and their families in times of disaster, all employees are required to give reports confirming their safety via a safety confirmation system. Use of this system is regularly practiced, with participation by all employees, twice a year.Example of Risk ManagementFramework for compliance implementationCorporate GovernanceCompliance and Risk ManagementCompliance Committeeof the group companiesin JapanCompliance Committeeof the group companiesoutside JapanCompliance Committeeof Sumitomo DainipponPharmaReport47Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#48

このブックを見る